184 related articles for article (PubMed ID: 29808285)
1. Galunisertib modifies the liver fibrotic composition in the Abcb4Ko mouse model.
Hammad S; Cavalcanti E; Werle J; Caruso ML; Dropmann A; Ignazzi A; Ebert MP; Dooley S; Giannelli G
Arch Toxicol; 2018 Jul; 92(7):2297-2309. PubMed ID: 29808285
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosis.
Luangmonkong T; Suriguga S; Bigaeva E; Boersema M; Oosterhuis D; de Jong KP; Schuppan D; Mutsaers HAM; Olinga P
Br J Pharmacol; 2017 Sep; 174(18):3107-3117. PubMed ID: 28691737
[TBL] [Abstract][Full Text] [Related]
3. Galunisertib suppresses the staminal phenotype in hepatocellular carcinoma by modulating CD44 expression.
Rani B; Malfettone A; Dituri F; Soukupova J; Lupo L; Mancarella S; Fabregat I; Giannelli G
Cell Death Dis; 2018 Mar; 9(3):373. PubMed ID: 29515105
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-β signaling pathway inhibitor galunisertib.
Li W; Tibben M; Wang Y; Lebre MC; Rosing H; Beijnen JH; Schinkel AH
Int J Cancer; 2020 Mar; 146(6):1631-1642. PubMed ID: 31304590
[TBL] [Abstract][Full Text] [Related]
5. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.
Herbertz S; Sawyer JS; Stauber AJ; Gueorguieva I; Driscoll KE; Estrem ST; Cleverly AL; Desaiah D; Guba SC; Benhadji KA; Slapak CA; Lahn MM
Drug Des Devel Ther; 2015; 9():4479-99. PubMed ID: 26309397
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis.
de Gouville AC; Boullay V; Krysa G; Pilot J; Brusq JM; Loriolle F; Gauthier JM; Papworth SA; Laroze A; Gellibert F; Huet S
Br J Pharmacol; 2005 May; 145(2):166-77. PubMed ID: 15723089
[TBL] [Abstract][Full Text] [Related]
7. Cirrhotic Human Liver Extracellular Matrix 3D Scaffolds Promote Smad-Dependent TGF-β1 Epithelial Mesenchymal Transition.
Mazza G; Telese A; Al-Akkad W; Frenguelli L; Levi A; Marrali M; Longato L; Thanapirom K; Vilia MG; Lombardi B; Crowley C; Crawford M; Karsdal MA; Leeming DJ; Marrone G; Bottcher K; Robinson B; Del Rio Hernandez A; Tamburrino D; Spoletini G; Malago M; Hall AR; Godovac-Zimmermann J; Luong TV; De Coppi P; Pinzani M; Rombouts K
Cells; 2019 Dec; 9(1):. PubMed ID: 31905709
[TBL] [Abstract][Full Text] [Related]
8. NGS-based transcriptome profiling reveals biomarkers for companion diagnostics of the TGF-β receptor blocker galunisertib in HCC.
Cao Y; Agarwal R; Dituri F; Lupo L; Trerotoli P; Mancarella S; Winter P; Giannelli G
Cell Death Dis; 2017 Feb; 8(2):e2634. PubMed ID: 28230858
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts.
Maier A; Peille AL; Vuaroqueaux V; Lahn M
Cell Oncol (Dordr); 2015 Apr; 38(2):131-44. PubMed ID: 25573078
[TBL] [Abstract][Full Text] [Related]
10. Exploring organ-specific features of fibrogenesis using murine precision-cut tissue slices.
Bigaeva E; Gore E; Mutsaers HAM; Oosterhuis D; Kim YO; Schuppan D; Bank RA; Boersema M; Olinga P
Biochim Biophys Acta Mol Basis Dis; 2020 Jan; 1866(1):165582. PubMed ID: 31676376
[TBL] [Abstract][Full Text] [Related]
11. A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Kelley RK; Gane E; Assenat E; Siebler J; Galle PR; Merle P; Hourmand IO; Cleverly A; Zhao Y; Gueorguieva I; Lahn M; Faivre S; Benhadji KA; Giannelli G
Clin Transl Gastroenterol; 2019 Jul; 10(7):e00056. PubMed ID: 31295152
[TBL] [Abstract][Full Text] [Related]
12. Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma.
Faivre S; Santoro A; Kelley RK; Gane E; Costentin CE; Gueorguieva I; Smith C; Cleverly A; Lahn MM; Raymond E; Benhadji KA; Giannelli G
Liver Int; 2019 Aug; 39(8):1468-1477. PubMed ID: 30963691
[TBL] [Abstract][Full Text] [Related]
13. Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.
Holmgaard RB; Schaer DA; Li Y; Castaneda SP; Murphy MY; Xu X; Inigo I; Dobkin J; Manro JR; Iversen PW; Surguladze D; Hall GE; Novosiadly RD; Benhadji KA; Plowman GD; Kalos M; Driscoll KE
J Immunother Cancer; 2018 Jun; 6(1):47. PubMed ID: 29866156
[TBL] [Abstract][Full Text] [Related]
14. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.
Serova M; Tijeras-Raballand A; Dos Santos C; Albuquerque M; Paradis V; Neuzillet C; Benhadji KA; Raymond E; Faivre S; de Gramont A
Oncotarget; 2015 Aug; 6(25):21614-27. PubMed ID: 26057634
[TBL] [Abstract][Full Text] [Related]
15. Galunisertib (LY2157299), a transforming growth factor-β receptor I kinase inhibitor, attenuates acute pancreatitis in rats.
Liu X; Yu M; Chen Y; Zhang J
Braz J Med Biol Res; 2016 Aug; 49(9):e5388. PubMed ID: 27509307
[TBL] [Abstract][Full Text] [Related]
16. TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.
Tran HC; Wan Z; Sheard MA; Sun J; Jackson JR; Malvar J; Xu Y; Wang L; Sposto R; Kim ES; Asgharzadeh S; Seeger RC
Clin Cancer Res; 2017 Feb; 23(3):804-813. PubMed ID: 27756784
[TBL] [Abstract][Full Text] [Related]
17. RAR-Related Orphan Receptor Gamma (ROR-γ) Mediates Epithelial-Mesenchymal Transition Of Hepatocytes During Hepatic Fibrosis.
Kim SM; Choi JE; Hur W; Kim JH; Hong SW; Lee EB; Lee JH; Li TZ; Sung PS; Yoon SK
J Cell Biochem; 2017 Aug; 118(8):2026-2036. PubMed ID: 27791279
[TBL] [Abstract][Full Text] [Related]
18. Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.
Capper D; von Deimling A; Brandes AA; Carpentier AF; Kesari S; Sepulveda-Sanchez JM; Wheeler HR; Chinot O; Cher L; Steinbach JP; Specenier P; Rodon J; Cleverly A; Smith C; Gueorguieva I; Miles C; Guba SC; Desaiah D; Estrem ST; Lahn MM; Wick W
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28481241
[TBL] [Abstract][Full Text] [Related]
19. Molecular Mechanism Responsible for Fibronectin-controlled Alterations in Matrix Stiffness in Advanced Chronic Liver Fibrogenesis.
Iwasaki A; Sakai K; Moriya K; Sasaki T; Keene DR; Akhtar R; Miyazono T; Yasumura S; Watanabe M; Morishita S; Sakai T
J Biol Chem; 2016 Jan; 291(1):72-88. PubMed ID: 26553870
[TBL] [Abstract][Full Text] [Related]
20. Fibronectin Type III Domain-Containing 5 Attenuates Liver Fibrosis Via Inhibition of Hepatic Stellate Cell Activation.
Zhou B; Ling L; Zhang F; Liu TY; Zhou H; Qi XH; Chen Q; Li YH; Kang YM; Zhu GQ
Cell Physiol Biochem; 2018; 48(1):227-236. PubMed ID: 30007970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
